**Table 2 Association between patient’s demographics and drug resistance (n = 1008)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variables** | **Isoniazid**  | **Rifampicin**  | **Ethambutol**  | **Streptomycin**  | **MDR-TB**  |
| **No** | **Yes** | **No** | **Yes** | **No** | **Yes** | **No** | **Yes** | **No** | **Yes** |
| **Total** | 747 (74.1%) | 261 (25.9%) | 899 (89.2%) | 109 (10.8%) | 978 (97.0%) | 30 (3.0%) | 900 (89.3%) | 108 (10.7%) | 916 (90.9%) | 92 (9.1%) |
| **Gender** |  |  |  |  |  |  |  |  |  |  |
|  | Female | 166 (72.8%) | 62 (27.2%) | 197 (86.4%) | 31 (13.6%) | 222 (97.4%) | 6 (2.6%) | 198 (86.8%) | 30 (13.2%) | 204 (89.5%) | 24 (10.5%) |
|  | Male | 581 (74.5%) | 199 (25.5%) | 702 (90.0%) | 78 (10.0%) | 756 (96.9%) | 24 (3.1%) | 702 (90.0%) | 78 (10.0%) | 712 (91.3%) | 68 (8.7%) |
|  | **p-value** | 0.610 | 0.125 | 0.728 | 0.175 | 0.405 |
| **Age group (years)** |  |  |  |  |  |  |  |  |  |  |
|  | < 60 | 586 (74.4%) | 202 (25.6%) | 693 (87.9%) | 95 (12.1%) | 765 (97.1%) | 23 (2.9%) | 698 (88.6%) | 90 (11.4%) | 709 (90.0%) | 79(10.0%) |
|  | ≥ 60 | 161 (73.2%) | 59 (26.8%) | 206 (93.6%) | 14 (6.4%) | 213 (96.8%) | 7 (3.2%) | 202 (91.8%) | 18 (8.2%) | 207 (94.1%) | 13 (5.9%) |
|  | **P-value** | 0.723 | 0.018 \* | 0.839 | 0.170 | 0.065 |
| **Residence place** |  |  |  |  |  |  |  |  |  |  |
|  | Rural | 224 (70.7%) | 93 (29.3%) | 265 (83.6%) | 52 (16.4%) | 304 (95.9%) | 13 (4.1%) | 281 (88.6%) | 36 (11.4%) | 274 (86.4%) | 43 (13.6%) |
|  | Urban | 532 (75.7%) | 168 (24.3%) | 634 (91.8%) | 57 (8.2%) | 674 (97.5%) | 17 (2.5%) | 619 (89.6%) | 72 (10.4%) | 642 (92.9%) | 49 (7.1%) |
|  | **P-value** | 0.091 |  < 0.001\* | 0.155 | 0.655 | 0.001\* |
| **TB treatment History** |  |  |  |  |  |  |  |  |  |  |
|  | Retreatment  | 186 (66.9%) | 92 (33.1%) | 227 (81.7%) | 51 (18.3%) | 268 (96.4%) | 10 (3.6%) | 241 (86.7%) | 37 (13.3%) | 236 (84.9%) | 42 (15.1%) |
|  | On treatment | 236 (68.6%) | 108 (31.4%) | 299 (86.9%) | 45 (13.1%) | 332 (96.5%) | 12 (3.5%) | 308 (89.5%) | 36 (10.5%) | 305 (88.7%) | 39 (11.3%) |
|  | Pre-treatment | 325 (84.2%) | 61 (15.8%) | 373 (96.6%) | 13 (3.4%) | 378 (97.9%) | 8 (2.1%) | 351 (90.9%) | 35 (9.1%) | 375 (97.2%) | 11 (2.8%) |
|  | **P-value** | < 0.001\* | < 0.001\* | 0.412 | 0.215 | < 0.001\* |

Values are presented as number (%).

\*p-values < 0.05 of the chi-square test.